MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rius, C.
Right arrow Articles by Aller, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rius, C.
Right arrow Articles by Aller, P.

Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression

C Rius, AR Zorrilla, C Cabanas, F Mata, C Bernabeu and P Aller

Centro de Investigaciones Biologicas, C.S.I.C., Madrid, Spain.

The administration of the DNA topoisomerase II inhibitors 4'-(9- acridinylamino)methanesulfon-m-anisidide (m-AMSA) (10(-7) M), VP-16 (2 x 10(-7) M), or novobiocin (1.5 x 10(-4) M) reduces the growth activity of human promonocytic leukemia U-937 cells, by arresting them preferentially at the G2 (m-AMSA and VP-16) or at the G1 and G2 (novobiocin) phases of the cell cycle. Under these conditions, m-AMSA and VP-16 induce the differentiation of the cells efficiently, as proved both by an increase in the production of reactive oxygen species and by the activation of the surface expression of CD11b and CD11c, two differentiation-specific antigens. Novobiocin also induces the expression of those differentiation markers, but to a lesser extent. Analyses by Northern blot indicate that the topoisomerase II inhibitors reduce the levels of c-myc and beta-actin mRNA and increase the levels of vimentin mRNA. The expression of vimentin is also stimulated at the protein level, as indicated by immunofluorescence assays. This represents one of the few known instances in which topoisomerase inhibitors stimulate gene expression in eukaryotic cells.

Volume 39, Issue 4, pp. 442-448, 04/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
I. Collins, A. Weber, and D. Levens
Transcriptional Consequences of Topoisomerase Inhibition
Mol. Cell. Biol., December 15, 2001; 21(24): 8437 - 8451.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Riesbeck, A. Forsgren, A. Henriksson, and A. Bredberg
Ciprofloxacin Induces an Immunomodulatory Stress Response in Human T Lymphocytes
Antimicrob. Agents Chemother., August 1, 1998; 42(8): 1923 - 1930.
[Abstract] [Full Text]

Home page
 J. Cell Sci.Home page
C Perez, N. Vilaboa, L Garcia-Bermejo, E de Blas, A. Creighton, and P Aller
Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action
J. Cell Sci., January 2, 1997; 110(3): 337 - 343.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
K. Tsutsui, K. Tsutsui, K. Sano, A. Kikuchi, and A. Tokunaga
Involvement of DNA Topoisomerase IIbeta in Neuronal Differentiation
J. Biol. Chem., February 16, 2001; 276(8): 5769 - 5778.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1991 by the American Society for Pharmacology and Experimental Therapeutics